JIN Yang Pharmaceutical
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
JIN Yang Pharmaceutical makes medicines, including both prescription drugs and over-the-counter products, used by patients and dispensed through hospitals, clinics, and pharmacies in South Korea.
The company also engages in importing and exporting pharmaceuticals. It is listed on KOSDAQ, South Korea's tech and small-cap exchange. Its product portfolio centres on generic medicines, drugs whose original patents have expired, which is the dominant model across the domestic Korean pharmaceutical industry.
Summary is AI-generated and may contain errors · figures from DART filings
JIN Yang Pharmaceutical in five facts
What does JIN Yang Pharmaceutical do?
JIN Yang Pharmaceutical makes medicines, including both prescription drugs and over-the-counter products, used by patients and dispensed through hospitals, clinics, and pharmacies in South Korea.
Where is JIN Yang Pharmaceutical listed and in which sector?
JIN Yang Pharmaceutical (Korean name: 진양제약) trades under KRX code 007370 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Health Care sector, Pharmaceuticals.
How large is JIN Yang Pharmaceutical?
Its market capitalisation was US$41.2M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were JIN Yang Pharmaceutical's latest annual revenue and operating profit?
For fiscal year 2025, JIN Yang Pharmaceutical reported revenue of US$91.1M, operating profit of US$1.9M and net income of US$16.8M, per its annual report on DART (data retrieved from DART on 2026-09-08). Revenue was up 6.5% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-08
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- [Amended] Cash/in-kind dividend decision
JIN Yang Pharmaceutical updated its declared cash dividend of US$0.10 per share.
Dividend · Feb 23 - Change of 30% or more in revenue or profit/loss structure (15% for large companies)
JIN Yang Pharmaceutical reported separate results for FY2025: revenue of US$83.4M (+6.49% year on year), operating profit of US$1.8M (−77.81% year on year) and net income of US$14.8M (−27.95% year on year).
Earnings · Feb 4